Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair Munro, Nick Andrews, Parvinder K. Aley et al.|The Lancet Infectious Diseases|2022Cited by 180
Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan AreaStephanie Berg, Santosh L. Saraf, Seohyun Kim et al.|Blood|2020Cited by 1